Ruzanna Papyan: Check out the latest findings on Molecular Classification of CNS Embryonal Tumors

Ruzanna Papyan shared a post by Rare Embryonal Tumors of the CNS International Registry, on LinkedIn:

“Check out the latest findings on Molecular Classification of CNS Embryonal Tumors. Insights reveal diverse tumor subtypes and treatment outcomes, shaping future strategies in CNS cancer care.”

Quoting Rare Embryonal Tumors of the CNS International Registry‘s post:

“This study is a remarkable illustration of how multinational, multi-center retrospective research can transform our understanding and demonstrate the impact of implementing molecular diagnostics on final diagnoses and risk-stratified treatments. This amazing study revealed that CNS NB-FOXR2 has a better prognosis compared to other rare CNS tumors.”

Read further.
Source: Ruzanna Papyan/LinkedIn and Rare Embryonal Tumors of the CNS International Registry/LinkedIn

Ruzanna Papyan is a pediatric oncologist and clinical research physician at the Pediatric Cancer and Blood Disorders Center of Armenia, Hematology  Center after Prof. Yeolyan. She is also Head of the Musculoskeletal Multidisciplinary Working Group and Assistant Professor at the Department of Pediatric Oncology and Hematology at Yerevan State Medical University. Dr. Papyan coordinates educational sessions for the Global Neuroblastoma Network and holds the esteemed position of co-chair of the Adolescents and Young Adults Steering Group at the International Society of Paediatric Oncology (SIOP). She is a member of oncology societies, such as AAHO, SOHO, ESMO, ESO, and POEM. Her research interests include soft tissue and bone sarcomas, and neuroblastomas among children and young adults.